

Icosapent Ethyl and Omega-3 Fatty Acids in Cardiovascular Protection

EVIDENCE. GUIDELINES. PRACTICAL APPLICATION.

FRANÇAIS VENDREDI 10 SEPTEMBRE 2021

08 00 h à 12 15 h HAE



Jean-Claude Tardif,
CM, M.D., FRCPC

COPRÉSIDENT

Université de Montréal,
Montréal (Qc)



Pierre Voisine,
M.D., FRCSC

COPRÉSIDENT

Université Laval,
Québec (Qc)

ENGLISH SATURDAY, SEPTEMBER 11, 2021

11 00 h - 15 15 h EDT



Lawrence A Leiter,
MD, FRCPC

CO-CHAIR

University of Toronto,
Toronto, ON



Mohammed Al-Omran,
MD, MSc, FRCSC

CO-CHAIR

University of Toronto,
Toronto, ON

ORDRE DU JOUR / AGENDA

		FRANÇAIS		ENGLISH	
André Bélanger, M.D., CFPC Clinique Médicale Valcartier, Shannon (Qc)	D ^r Jean-Claude Tardif 08 00 h	Opening Remarks		11 00 h	Dr. Lawrence Leiter
Jean-Marie Ekoé, M.D., CSPQ, PD Université de Montréal, Montréal (Qc)	D ^r Jean-Claude Tardif 08 10 h	Let's get the terminology straight		11 10 h	Dr. Subodh Verma
Daniel Gaudet, M.D., Ph. D. Université de Montréal, Montréal (Qc)	D ^r Simon Kouz 08 25 h	The JELIS trial: Implications for IPE		11 25 h	Dr. Vineeta Ahooja
Jean C. Grégoire, M.D., FRCPC Université de Montréal, Montréal (Qc)	D ^r Jean-Claude Tardif 08 35 h	The REDUCE-IT trial: What were the main results?		11 35 h	Dr. Deepak Bhatt
Simon Kouz, M.D., FRCPC CISSS de Lanaudière, Joliette (Qc)	D ^r Jean-Marie Ekoé 08 55 h	IPE for patients with diabetes		11 55 h	Dr. Alice Cheng
Samer Mansour, M.D., CSPQ, FRCPC Université de Montréal, Montréal (Qc)	D ^r Pierre Voisine 09 10 h	IPE for patients with a prior PCI or CABG		12 10 h	Dr. Kevin Bainey
Hugues Provencher-Couture, M. Sc., Infirmier praticien spécialisé en cardiologie CIUSSS de l'Estrie-CHUS, Sherbrooke (Qc)	D ^r Theodore Wein 09 25 h	IPE for stroke prevention		12 25 h	Dr. Theodore Wein
09 40 h		Q&A		12 40 h	
D ^r Jean Grégoire 10 05 h		Key learnings from the trials with non-EPA omega-3 fatty acids		13 05 h	Dr. Priya Manjoo
D ^r Samer Mansour 10 20 h		Safety of IPE: What clinicians should know?		13 20 h	Dr. Lawrence Leiter
D ^r George Thanassoulis 10 35 h		The mechanisms of IPE and vascular protection		13 35 h	Dr. Preston Mason
D ^r Daniel Gaudet 10 50 h		Beyond LDL-C: What do lipids and other lipoproteins tell us about CV risk?		13 50 h	Dr. Robert Hegele
D ^r George Thanassoulis 11 05 h		Canadian Clinical Practice Guideline Update		14 05 h	Dr. Subodh Verma
Hugues Provencher-Couture 11 20 h		Case-based Discussion I		14 20 h	Marnee Wilson
D ^r André Bélanger 11 35 h		Case-based Discussion II		14 35 h	Dr. Basel Bari
11 50 h		Q&A		14 50 h	
D ^r Pierre Voisine 12 15 h		Closing Remarks		15 15 h	Dr. Mohammed Al-Omran

LEARNING OBJECTIVES


1. Differentiate between the different types of omega-3 fatty acids
2. Describe the major findings of the omega-3 fatty acid trials
3. Explain how a purified form of an omega-3 fatty acid may be vasculoprotective
4. Recognize the patients who would benefit clinically from use of the purified form of an omega-3 fatty acid

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Association of Pathologists – Association canadienne des pathologistes. You may claim a maximum of 2.0 hours (credits are automatically calculated.) In compliance with Innovative Medicines Canada Code of Ethical Practices, this invitation is extended to Healthcare Professionals only.

Veuillez vous inscrire au webinaire du
10 septembre au : www.IPESymposiaFR.com

For September 11, please register at:
www.IPESymposiaEN.com

For more information about this program please contact S&L Solutions at
647-462-1138 or info@slsolutionevents.ca



Theodore Wein,
MD, FRCPC
McGill University,
Montreal, QC

Marnee Wilson,
MSc(N), CDE,
NP-Adult
St Michael's Hospital,
Toronto, ON